Pharmaceutical compositions
First Claim
Patent Images
1. A composition adapted for the oral administration of a selected proteinaceous material in biologically active form, said composition comprising:
- (a) particles having an average diameter of approximately 1 to about 100 microns and consisting essentially of a solid emulsifying agent and a surfactant;
(b) a selected biologically active proteinaceous material bound to the surface of said particles with a binder agent; and
(c) a lipid coating having a thickness of approximately 0.05 to about 1.0 microns surrounding said particles having said proteinaceous material bound to their surfaces.
1 Assignment
0 Petitions
Accused Products
Abstract
A composition adapted to administer a pharmocologically effective amount of a pharmaceutical agent when ingested orally comprising (a) a pharmaceutical agent; (b) a lipid coating materials; and (c) an enteric coating materials optionally comprising water soluble coating materials; emulsifying and solubilizing agents; binding agents; stabilizing and enzyme inhibiting agents surfactants and antimicrobial agents. The composition can also include a low density lipoprotein composition and lipolytic enzymes.
327 Citations
69 Claims
-
1. A composition adapted for the oral administration of a selected proteinaceous material in biologically active form, said composition comprising:
-
(a) particles having an average diameter of approximately 1 to about 100 microns and consisting essentially of a solid emulsifying agent and a surfactant; (b) a selected biologically active proteinaceous material bound to the surface of said particles with a binder agent; and (c) a lipid coating having a thickness of approximately 0.05 to about 1.0 microns surrounding said particles having said proteinaceous material bound to their surfaces. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)
-
-
18. A composition adapted for the oral administration of insulin in biologically active form, said composition comprising:
-
(a) particles having an average diameter of from about 1 to about 100 microns and consisting essentially of cholesterol, sodium lauryl sulfate and, methyl and propylparabens; (b) insulin bound to the surface of said particles with a solution consisting essentially of hydroxypropylcellulose, sodium lauryl sulfate, triethylamine HCl and citric acid; (c) a lipid coating having a thickness of from about 0.1 to 0.3 microns; and (d) an enteric coating layer comprising hydroxypropylmethylcellulose phthalate, shellac and PEG-6000 with the thickness of 0.1 microns surrounding said polyethylene glycol monostearate coating on said particles.
-
-
19. A method for the preparation of compositions adapted for oral administration of selected proteinaceous material in biologically active form comprising the steps:
-
(a) forming particles having an average diameter of from about 1 micron to 1/2 millimeter and consisting essentially of a solid emulsifying agent and a surfactant; (b) binding a selected biologically active proteinaceous material to the surfaces of said particles with a binder agent; and (c) coating said particles having said proteinaceous material bound to their surfaces with a lipid coating layer having a thickness of 0.05 to 1.0 microns. - View Dependent Claims (20, 21, 22, 23, 24)
-
-
25. A composition adapted for the oral administration of insulin in biologically active form comprising:
-
particles having an average diameter of approximately 1 to 100 microns consisting essentially of an emulsifying agent and a surfactant; insulin bound to the surface of the particles; a lipid coating surrounding the particles having the proteinaceous material bond to their surfaces; and an enteric coating layer surrounding the lipid coating.
-
-
26. A method of orally administering insulin comprising:
providing a composition for oral ingestion comprising insulin bound to a surface of a solid emulsifier/solubilizing particle, the insulin and particles being coated with a lipid coating, the particles having an average diameter of approximately 1 micron to about 100 microns, and the lipid coating being coated by an enteric coating.
-
27. A method orally administering insuling composition:
providing a composition for oral ingestion comprising insulin bound to a surface of lipoprotein particles, the insulin and particles being coated by a lipid coating, and the lipid coating being coated by an enteric coating. - View Dependent Claims (28, 29)
-
30. A composition adapted for the oral administration of a selected proteinaceous material in biologically active form, said composition comprising:
-
(a) a lipoprotein composition; (b) a selected biologically active proteinaceous material bound to the surface of the lipoprotein composition; and (c) a lipid coating surrounding said lipoprotein composition and proteinaceous material. - View Dependent Claims (31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50)
-
-
51. A composition adapted for the oral administration of insulin in biologically active form, said composition comprising:
-
(a) particles having an average diameter of from about 1 micron to about 1/2 millimeter and including a low density of lipoprotein composition; (b) insulin bound to the surface of said particles with a binder; (c) a water soluble coating layer, for coating the particles and insulin; and (d) a lipid coating for coating the water soluble layer, particles and insulin. - View Dependent Claims (52, 53)
-
-
54. A method for the preparation of compositions adapted for the oral administration of selected proteinaceous material in biologically active form comprising the steps of:
-
(a) forming low density lipoprotein particles having an average diameter of from about 1 micron to 1/2 millimeter; (b) binding a selected biologically active proteinaceous material to the surfaces of said particles with a binder agent; (c) coating the particles and proteinaceous material with a water soluble coating; and (d) coating the water soluble coated particles having said proteinaceous material bound to their surfaces with a lipid coating layer having a thickness of 0.05 to 1.0 microns. - View Dependent Claims (55, 56, 57)
-
-
58. A composition adapted for the oral administration of insulin in biologically active form comprising:
-
low density lipoprotein particles; insulin bound to the surface of the particles; a water soluble coating surrounding the particles and insulin; a lipid coating surrounding the water soluble coating and particles having insulin bound to their surfaces; a gel capsule for surrounding the lipid coating; and an enteric coating layer surrounding the gel capsule.
-
-
59. A method of treating diabetes comprising the steps of:
-
administering orally at least one capsule having a composition including a low density lipoprotein, insulin bound to the lipoprotein, a water soluble coating over the insulin and lipoprotein, and a lipid coating over the water soluble coating; and administering orally at least one capsule having a composition icluding lipolytic enzymes and bile salts.
-
-
60. The method of treating diabetes comprising the steps of:
-
administering orally at least one capsule having a composition including emulsifier/solubilizer particles, insulin bound to the particles, and a lipid coating over the particles; and administering orally at least one capsule having a composition including lipolytic enzymes.
-
- 61. A composition useful for the oral administration of a proteinaceous compound comprising lipolytic enzymes selected from the group including, pancreatic lipase, amylase, protease, and bile salts.
-
63. A composition adapted for the oral administration of insulin comprising the following components:
-
(a) particles of pancreatic lipase; (b) particles of bile salt; (c) lipid coated insulin bound lipid particles; (d) sodium bicarbonate; and (e) citric acid. - View Dependent Claims (64, 65, 66, 67, 68)
-
-
69. A composition adapted for the oral administration of insulin comprising a sodium bicarbonate and citric acid mixture in a ratio of approximately 3:
- 1 to about 1;
1, the mixture forming a seed that is coated with a layer of an insulin lipid mixture, and a resultant particle is then coated with an enteric coating.
- 1 to about 1;
Specification